Blood Cancer: Archives News of the month
Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification models
Blood Cancer 6 min.
The term “big data” has become a buzzword in medical literature, yet its interpretation varies significantly between medical professionals and data scientists. For instance, ImageNet1 (https://www.image-net.org/)—an object-based image database frequently used for training and validation...
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management
Blood Cancer 3 min.
The small molecule selective inhibitor of B-cell lymphoma-2 (BCL-2), venetoclax [1], was approved in Japan in 2021 with azacitidine (VEN/AZA) or low-dose cytarabine (VEN/LDAC) for acute myeloid leukemia (AML) [2]. Despite significantly improving AML outcomes versus a hypomethylating agent (HMA) or low-dose...
An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib – a case report and literature review
Blood Cancer 3 min.
Histiocytic sarcoma (HS) developing as a secondary neoplasm is extraordinarily rare [1] in childhood and presents a diagnostic challenge. Dismal prognosis is expected due to rapid progression and poor response to therapy [2]. No optimal treatment has been defined and standardized [3]. Among the reported...
Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram
Blood Cancer 7 min.
Acute myeloid leukemia (AML), a heterogeneous hematologic malignancy marked by abnormal proliferation of myeloid blasts or progranulocytes lacking differentiation, is the most common acute leukemia in adults and the leading cause of leukemia-related deaths globally. Outcomes for patients with AML are...
Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia
Blood Cancer 9 min.
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic tumor caused by the abnormal proliferation and differentiation of myeloid cells. AML has different subtypes due to its wide range of cytogenetic and molecular abnormalities. Chemotherapy as the standard treatment for AML [1, 2], about 10–40%...
